Fate Therapeutics stock gained 4.74 percent on October 5

Published on 10/06/2026 at 12:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fate Therapeutics stock gained after the company granted 62,900 options at USD 2.30 on October 1. Second-quarter revenue reached USD 2.08 million versus USD 1.94 million consensus.

FATE, US31189P1021, Illustration mit AI erstellt.

Fate Therapeutics (ISIN US31189P1021) was last at USD 2.43 on Nasdaq on October 5, 2026, up 4.74 percent from the prior close. The latest company event involved equity awards for new employees, while second-quarter revenue also exceeded the published consensus estimate.

Fresh awards set the tone

According to GlobeNewswire on October 2, 2026, Fate Therapeutics granted options on 62,900 shares at an exercise price of USD 2.30, matching the Nasdaq closing price on October 1. The company also granted restricted stock units representing 72,700 shares to two new employees, with both award types vesting over four years.

The awards are an employee-retention measure rather than a financing transaction. Their scale is small relative to the 118.5 million-share float cited in current market coverage, but the USD 2.30 exercise price sits below the October 5 last price of USD 2.43.

Revenue beat meets heavy losses

MarketBeat reported that second-quarter 2026 revenue was USD 2.08 million, versus a consensus estimate of USD 1.94 million, a 7.2 percent beat. Diluted EPS was negative USD 0.25, matching consensus, while the quarter produced a net loss of USD 30.159 million.

Fate Therapeutics generated USD 2.082 million of revenue in Q2/2026 compared with USD 1.299 million in Q1/2026, a 60.3 percent sequential increase. Cash and cash equivalents stood at USD 32.429 million on June 30, 2026, while operating cash flow was negative USD 23.434 million for the quarter.

Analysts see a wide valuation gap

In a report dated October 5, 2026, Needham analyst Gil Blum maintained a Hold rating, as Markets Insider reported. The same report described a Moderate Buy consensus with a USD 6.70 average target, while MarketBeat lists a Hold consensus, eight analysts and a USD 5.90 average target.

Using the October 5 price of USD 2.43, the MarketBeat average target lies 142.8 percent above the stock price. The latest quote also sits between the 52-week low of USD 0.95 and high of USD 3.23, leaving clinical execution and cash use as the central numbers for the investment case.

Fate Therapeutics stock stays volatile

Fate Therapeutics stock was last at USD 2.43 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, with volume of 3,379,467 shares. Market capitalization was USD 283.2 million on that date, and the 4.74 percent daily gain followed a prior close of USD 2.32.